Skip to main content

Advertisement

SpringerLink
Log in

Safety and comfort of domestic bortezomib injection in real-life experience

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy is often short. We report our evaluations upon safety and efficacy of domestic subcutaneous bortezomib in elderly and frail patients candidate to bortezomib-melphalan-prednisone (VMP) regimen. We confirmed that overall incidence of adverse events, including peripheral neuropathy, was low, and in no case required admission to emergency service, contributing to reduce the rate of therapy discontinuation. These results confirm the effectiveness and safety of subcutaneous bortezomib, in a real-life-experience, and define a new possibility of safe auto-administration in a comfortable domestic setting. We suggest that domestic treatment can significantly improve the quality of life of the patients, avoiding unnecessary transfer to the hospital without reducing treatment efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK (2017) Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst 109(9). https://doi.org/10.1093/jnci/djx030

  2. Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, Cakana A, Velde H, Richardson PG, San Miguel JF (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89(1):16–27

    Article  PubMed  CAS  Google Scholar 

  3. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 82(2):93–105

    Article  PubMed  Google Scholar 

  4. Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH (2010) Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean multiple myeloma working party (KMMWP). Ann Hematol 89(5):489–497

    Article  PubMed  CAS  Google Scholar 

  5. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A, Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omede P, Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A (2011) Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117(11):3025–3031

    Article  PubMed  CAS  Google Scholar 

  6. Gozzetti A, Fabbri A, Oliva S, Marchini E, Bocchia M, Defina M, Lauria F (2010) Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 10(1):68–72

    Article  PubMed  CAS  Google Scholar 

  7. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ (2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25(4):689–696

    Article  PubMed  CAS  Google Scholar 

  8. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, Lopez de la Guia A, Lopez J, Bengoechea E, Perez M, Polo M, Palomera L, de Arriba F, Gonzalez Y, Hernandez JM, Granell M, Bello JL, Bargay J, Penalver FJ, Ribera JM, Martin-Mateos ML, Garcia-Sanz R, Lahuerta JJ, Blade J, San-Miguel JF (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120:2581–2588

    Article  PubMed  CAS  Google Scholar 

  9. Zweegman S, Engelhardt M, Larocca A (2017) Elderly patients with multiple myeloma: towards a frailty approach? Curr Opin Oncol 29(5):315–321

    Article  PubMed  Google Scholar 

  10. M G VM, M O PM, S B MTP et al (2017) Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: a comparison of two prospective trials. Am J Hematol 3:244–250

    Google Scholar 

  11. Romano A, Conticello C, Di Raimondo F (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5(4):327–352

    Article  PubMed  CAS  Google Scholar 

  12. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86(1):23–31

    Article  PubMed  CAS  Google Scholar 

  13. Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Pia Falcone A, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol 28:5101–5109

    Article  CAS  Google Scholar 

  14. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, vanRhee F, Barlogie B (2013) Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 27(1):226–232

    Article  PubMed  CAS  Google Scholar 

  15. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, Harousseau JL (2008) Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 93:1908–1911

    Article  PubMed  CAS  Google Scholar 

  16. Moreau P, Karamanesht II, Domnikova N, Kyselyova MY, Vilchevska K, Doronin VA, et al. (2011) Pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: effects of subcutaneous injection site and concentration, and patient characteristics. ASH Annual Meeting Abstracts 118(21):1863

  17. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440

    Article  PubMed  Google Scholar 

  18. Larocca A, Palumbo A (2015) How I treat fragile myeloma patients. Blood 126(19):2179–2185

    Article  PubMed  CAS  Google Scholar 

  19. Walker SE, Charbonneau LF, Law S (2014) Stability of bortezomib 2.5 mg/mL in vials and syringes stored at 4 degrees C and room temperature (23 degrees C). Can J Hosp Pharm 67(2):102–107

    PubMed  PubMed Central  Google Scholar 

  20. Bolognese A, Esposito A, Manfra M, Catalano L, Petruzziello F, Martorelli MC et al (2009) An NMR study of bortezomib degradation under clinical use conditions. Adv Hematol 2009:704928

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Leveque D (2014) Subcutaneous administration of anticancer agents. Anticancer Res 34(4):1579–1586

    PubMed  CAS  Google Scholar 

  22. Levêque D, Carvalho MC, Review MF (2007) Clinical pharmacokinetics of bortezomib. In Vivo 21(2):273–278

    PubMed  Google Scholar 

  23. Mateos MV (2011) Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 12(5):410–411

    Article  PubMed  Google Scholar 

  24. Cerchione C, Lucignano M, Pane F, Catalano L (2016) Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al. Eur J Haematol 96(5):544. https://doi.org/10.1111/ejh.12705

    Article  PubMed  Google Scholar 

  25. Romano A, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C et al (2014) Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. Eur J Haematol 93(3):207–213

    Article  PubMed  CAS  Google Scholar 

  26. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F, National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Cancer Netw 7(9):908–942

    Article  Google Scholar 

  27. Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301–302

    Article  PubMed  Google Scholar 

  28. Cerchione C, Catalano L, Peluso I, Nappi D, Di Perna M, Salvatore D et al (2016) Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone. Support Care Cancer 24(12):4835–4837

    Article  PubMed  PubMed Central  Google Scholar 

  29. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346

    Article  PubMed  Google Scholar 

  30. Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, de Paz R et al (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 11:934–941

    Article  PubMed  CAS  Google Scholar 

  31. Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, Garcia-Larana J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF (2008) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 93:560–565

    Article  PubMed  CAS  Google Scholar 

  32. Spicka I, Mateos MV, Redman K, Dimopoulos MA, Richardson PG (2011) An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. Immunotherapy 3(9):1033–1040

    Article  PubMed  CAS  Google Scholar 

  33. Bringhen S, Larocca A, Rossi D, Romano A, Genuardi M, Ria R et al (2010) Efficacy and safety of once weekly bortezomib in multiple myeloma patients. Blood 116(21):1248–1249

    Google Scholar 

  34. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S, on behalf of the International Myeloma Workshop Consensus Panel 3 (2011) Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 117(18):4701–4705

    Article  PubMed  CAS  Google Scholar 

  35. Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P (2012) Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 97(12):1925–1928

    Article  PubMed  PubMed Central  Google Scholar 

  36. Touati M, Lamarsalle L, Moreau S, Vergnenegre F, Lefort S, Brillat C et al (2016) Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in outpatient hospital and hospital care at home. Support Care Cancer 24(12):5007–5014

    Article  PubMed  PubMed Central  Google Scholar 

  37. Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M (2014) Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: a retrospective case-matched study. Am J Hematol 89(4):355–362

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology, Department of Clinical Medicine and Surgery, University Federico II, Via Pansini 5, 80131, Naples, Italy

    Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, Maria Di Perna, Irene Zacheo, Marco Picardi, Fabrizio Pane & Lucio Catalano

Authors
  1. Claudio Cerchione
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Nappi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Emanuele Pareto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Di Perna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Irene Zacheo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marco Picardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fabrizio Pane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lucio Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudio Cerchione.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cerchione, C., Nappi, D., Pareto, A.E. et al. Safety and comfort of domestic bortezomib injection in real-life experience. Support Care Cancer 26, 3111–3116 (2018). https://doi.org/10.1007/s00520-018-4155-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-018-4155-8

Keywords

Search

Navigation